{"id":"intravenous-iclaprim-or-intravenous-linezolid","safety":{"commonSideEffects":[{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL2109039","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Iclaprim is a synthetic antibiotic that selectively inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. This action prevents the formation of the 70S initiation complex, thereby inhibiting protein synthesis and ultimately leading to bacterial cell death.","oneSentence":"Iclaprim inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:46.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated skin and skin structure infections"},{"name":"Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia"}]},"trialDetails":[{"nctId":"NCT00299520","phase":"PHASE3","title":"Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)","status":"COMPLETED","sponsor":"Arpida AG","startDate":"2005-06","conditions":"Complicated Skin and Skin Structure Infection","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"intravenous iclaprim or intravenous linezolid","genericName":"intravenous iclaprim or intravenous linezolid","companyName":"Arpida AG","companyId":"arpida-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iclaprim inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Used for Complicated skin and skin structure infections, Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}